Breast Cancer Brain Metastases: Key Strategies for Optimal Management

December 12, 2019
This activity, certified for CME/CE/CPE credit, is jointly provided by

Breast Cancer Brain Metastases: Key Strategies for Optimal Management

A CE-Certified Satellite Symposium Held in Conjunction With

the 42nd Annual San Antonio Breast Cancer Symposium® on

Thursday, December 12 at 7:30 pm

This activity is designed to help clinicians achieve specific learning objectives, which reflect the desired results of the education. Participants are encouraged to integrate what they learn from this activity into practice to improve patient care and outcomes.

Harborside Medical Education

Harborside Medical Education (HSME), a division of Harborside, is committed to advancing care for people with cancer and improving patient outcomes through professional continuing education (CE) activities in oncology that address practice gaps and promote change in learners’ knowledge, competence and performance in both community and academic practice settings.

Release date: December 12, 2019

Expiration date: December 12 , 2020

Estimated time to complete activity: 1.5 hours

Certified for CE by:

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Drive, Dinah Shore Bldg.
Rancho Mirage, CA 92270
Voice: 760-773-4500
Fax: 760-773-4513

© 2019, Annenberg Center for Health Sciences at Eisenhower. All rights reserved.

This activity is supported by educational grants from Puma Biotechnology, Inc. and Seattle Genetics, Inc.


Lee Schwartzberg, MD, FACP, West Cancer Center

Nancy U. Lin, MD, Dana-Farber Cancer Institute

Carey K. Anders, MD, Duke Cancer Institute

Intended Audience

Oncology clinicians who treat patients with breast cancer at risk for developing, or who have developed, brain metastases

Learning Objectives

After completing this educational activity, participants should be able to:

  1. Assess new findings related to the biology and pathogenesis of breast cancer brain metastases (BCBM)
  2. Evaluate emerging data for current and novel therapies for managing BCBM
  3. Plan strategies for managing BCBM, including management of treatment-related adverse events, in accordance with evidence-based data and clinical guidelines

Continuing Education

Statement of Credit—Participants who successfully complete this activity (including the submission of the post-test and evaluation form) will receive a statement of credit.



This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Harborside Medical Education. The Annenberg Center is accredited by the ACCME to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



The Annenberg Center for Health Sciences at Eisenhower is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

A maximum of 1.5 contact hours may be earned for successful completion of this activity.

Provider approved by the California Board of Registered Nursing, Provider No. 13664, for 1.5 contact hours.



The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

This activity has been assigned ACPE Universal Program # 0797-9999-19-110-L01-P. This activity is designated for up to 1.5 contact hour (0.15 CEU) of continuing pharmacy education credit. This is a knowledge-based activity.


Financial Disclosures

All individuals in a position to control the content of this activity (eg, planners, faculty, reviewers) must disclose all financial relationships with commercial interests that may have a bearing on its subject matter. The Annenberg Center for Health Sciences at Eisenhower has identified and resolved all conflicts of interest in accordance with its policies and procedures. Participants should assess the impact (if any) of the disclosed information on the educational value of the activity.



Lee Schwartzberg, MD, FACP

Consultant: Amgen, AstraZeneca, Genentech/Roche, Pfizer

Nancy U. Lin, MD

Consultant/advisor: Daiichi Sankyo, Puma Biotechnology, Seattle Genetics

Research support: Genentech, Merck, Pfizer, Seattle Genetics

Carey K. Anders, MD

Consultant/advisor: Eisai, Genentech, Ipsen

Research support: G-1 Therapeutics, Merck, Nektar, Lilly, Puma Biotechnology, Seattle Genetics, Tesaro

Annenberg Center for Health Sciences at Eisenhower

Charles Willis, Director of Continuing Education, consults for Pfizer, Inc. All other staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

Lead Nurse Planner

Dorothy Caputo, MA, BSN, RN, EduPro Resources, LLC, has nothing to disclose.


Harborside and Harborside Medical Education staff have no potential conflicts of interest to disclose.

Content Reviewers

Elizabeth Reed: research grant from Pfizer/NCCN


This activity has been designed to provide continuing education that is focused on specific objectives. In selecting educational activities, clinicians should pay special attention to the relevance of those objectives and the application to their particular needs. The intent of all Annenberg Center for Health Sciences at Eisenhower educational opportunities is to provide learning that will improve patient care. Clinicians are encouraged to reflect on this activity and its applicability to their own patient population.

The opinions expressed in this activity are those of the faculty and reviewers and do not represent an endorsement by Annenberg Center for Health Sciences at Eisenhower of any specific therapeutics or approaches to diagnosis or patient management.

Product Disclosure

This educational activity may contain discussion of published as well as investigational uses of agents that are not approved by the US Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product.

Statement of Credit

Participants who successfully complete this activity—which includes submitting a completed pre-test, submitting and scoring at least 70% on the post-test, and submitting a completed evaluation form—will be able to download a statement of credit.

Course summary
Available credit: 
  • 1.50 ACPE
  • 1.50 AMA PRA Category 1 Credit(s)™
  • 1.50 Attendance
  • 1.50 CA-BRN
  • 1.50 ANCC
Course opens: 
Course expires: 
Event starts: 
12/12/2019 - 7:30pm
Event ends: 
12/12/2019 - 9:00pm
San Antonio, TX
United States

Available Credit

  • 1.50 ACPE
  • 1.50 AMA PRA Category 1 Credit(s)™
  • 1.50 Attendance
  • 1.50 CA-BRN
  • 1.50 ANCC


Please login or register to take this course.